Neurocrine Biosciences Identifies Clinically Meaningful Health Improvement Threshold For INGREZZA In Tardive Dyskinesia Patients
New analysis establishes a 6-point increase on the EQ Visual Analogue Scale as a threshold for clinically meaningful change in overall health ratings in patients with tardive dyskinesia treated with
Neurocrine found a clear way to measure if their tardive dyskinesia medicine actually helps patients feel better. When doctors see this improvement signal, they know the medicine is truly working for that person.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.